Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Children Toxine Botulinum Detrusor Injection in Neurogenic Vesical Hyperactivity Syndrom
NCT02816151Phase 3Completed
- Sponsor
- CHU de Reims
- Start
- Feb 2011
- Primary completion
- May 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of botulinum toxin type A in neurogenic detrusor overactivity (NDO) (2 arms), sponsored by CHU de Reims. Primary endpoint: Detrusor pressure decrease in neurogenic vesical hyperactivity syndrome at 6 weeks. Started Feb 2011; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
neurogenic detrusor overactivity (NDO)
Beyond the preview
Go deeper on NCT02816151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02816151.